Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

News   Apr 22, 2008

 
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
 
 
 

RELATED ARTICLES

The Resilience of the Down's Syndrome Genome

News

People with Down's Syndrome have a genome optimised against rare mutation and a well-balanced gene expression rate, a study suggests.

READ MORE

CRISPR Technology Used to Make Stem Cells

News

In a world first, CRISPR genome editing has been used to reprogram skin cells to function as pluripotent stem cells.

READ MORE

Magnetic MicroRNAs Could Help Treat Incontinence

News

An unlikely combination of magnets and MicroRNAs might be a novel treatment for constipation and incontinence patients.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Applied Sciences Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE